ABCL

13.74

1.22% -0.17

Dopo l'orario di chiusura: 13.79 0.05 +0.36%

Abcellera Biologics Inc (ABCL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ABCL Giù? Forum Previsione

Precedente Chiudi:

$13.91

Aprire:

$14.095

Volume 24 ore:

3.69M

Relative Volume:

0.54

Capitalizzazione di mercato:

$4.45B

Reddito:

$79.21M

Utile/perdita netta:

$-143.96M

Rapporto P/E:

-28.65

EPS:

-0.4796

Flusso di cassa netto:

$-189.60M

1 W Prestazione:

+8.19%

1M Prestazione:

+20.95%

6M Prestazione:

+290.34%

1 anno Prestazione:

+129.77%

Intervallo 1D:

$13.66

$14.30

Intervallo di 1 settimana:

$12.38

$15.02

Portata 52W:

$2.745

$15.02

Abcellera Biologics Inc Stock (ABCL) Company Profile

Nome

Abcellera Biologics Inc

Settore

Healthcare (1064)

Industria

Biotechnology (595)

Telefono

(604) 559-9005

Indirizzo

150 W 4TH AVENUE, VANCOUVER

Dipendente

562

Cinguettio

Prossima data di guadagno

2026-11-05

Ultimi documenti SEC

ABCL's Discussions on Twitter

Compare ABCL vs VRTX, MRNA, REGN, ARGX, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ABCL Abcellera Biologics Inc	13.74	4.12B	79.21M	-143.96M	-189.60M	-0.4796
VRTX Vertex Pharmaceuticals Inc	504.73	133.37B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-11-07	Downgrade	Leerink Partners	Outperform → Market Perform
2025-07-07	Ripresa	Leerink Partners	Outperform
2024-08-20	Downgrade	The Benchmark Company	Buy → Hold
2024-02-22	Aggiornamento	The Benchmark Company	Hold → Buy
2023-12-05	Iniziato	KeyBanc Capital Markets	Overweight
2023-11-06	Downgrade	The Benchmark Company	Buy → Hold
2023-10-13	Ripresa	Piper Sandler	Overweight
2023-02-28	Iniziato	Cowen	Outperform
2022-12-15	Iniziato	Goldman	Buy
2022-11-16	Iniziato	Truist	Buy
2021-12-21	Iniziato	The Benchmark Company	Buy
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-01-05	Iniziato	BMO Capital Markets	Outperform
2021-01-05	Iniziato	Berenberg	Buy
2021-01-05	Iniziato	Credit Suisse	Outperform
2021-01-05	Iniziato	SVB Leerink	Outperform
2021-01-05	Iniziato	Stifel	Buy

Mostra tutto

Abcellera Biologics Inc Borsa (ABCL) Ultime notizie

Oct 01, 2026

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 - Business Wire

Oct 01, 2026

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment - marketscreener.com

Oct 01, 2026

Sep 30, 2026

Total equity of AbCellera Biologics, Inc. – HAN:8QQ - TradingView

Sep 30, 2026

JPMorgan Initiates AbCellera Biologics at Overweight With $17 Price Target - Moomoo

Sep 30, 2026

J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17 - Moomoo

Sep 29, 2026

ABCL Initiated Coverage By JP Morgan -- Rating Set to Overweight - GuruFocus

Sep 29, 2026

Why is Abcellera Biologics stock climbing today? By Investing.com - Investing.com Canada

Sep 29, 2026

Sep 28, 2026

Abcellera Biologics stock hits 52-week high at 13.23 USD - Investing.com

Sep 28, 2026

Sep 24, 2026

Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits

Sep 24, 2026

Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13 - moomoo.com

Sep 24, 2026

ABCL Reinstated by Goldman Sachs -- Neutral Rating with Price Ta - GuruFocus

Sep 24, 2026

AbCellera Biologics Price Target Announced at $13.00/Share by Goldman Sachs - Moomoo

Sep 24, 2026

Goldman Sachs resumes AbCellera stock coverage with neutral rating - Investing.com

Sep 24, 2026

Goldman Sachs resumes AbCellera stock coverage with neutral rating By Investing.com - Investing.com Canada

Sep 24, 2026

ABCL Looks 201.0% Overvalued on GF Value™ - GuruFocus

Sep 24, 2026

Sep 22, 2026